Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood

---

Copy For Citation

GÜMÜŞ E., Karaca O., BABAOĞLU M. Ö., BAYSOY G., Balamtekin N., DEMİR H., ...More

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, vol.68, no.5, pp.629-636, 2012 (SCI-Expanded)

• Publication Type: Article / Article
• Volume: 68 Issue: 5
• Publication Date: 2012
• Doi Number: 10.1007/s00228-011-1151-z
• Journal Name: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Page Numbers: pp.629-636
• Keywords: Lansoprazole, CYP2C19, Phenotyping, Genotyping, Children, S-MEPHENYTOIN OXIDATION, PROTON PUMP INHIBITORS, CYP2C19-ASTERISK-17 ALLELE, GENETIC POLYMORPHISMS, CYP2C19 ACTIVITY, BREATH TEST, PROGUANIL METABOLISM, DRUG-METABOLISM, OMEPRAZOLE, PHARMACOKINETICS
• Hacettepe University Affiliated: Yes

Abstract

Lansoprazole, a cytochrome P450 2C19 (CYP2C19) substrate, has been widely used in children to manage acid-related diseases. CYP2C19 exhibits marked genetic polymorphisms, and distribution of these polymorphisms varies among different ethnic groups. There is limited data regarding the use of probe drugs for determining CYP2C19 activity in children. The aim of this study was to evaluate lansoprazole as an in vivo phenotyping probe for assessing CYP2C19 activity in children.